Advertisement

Topics

Arch Oncology raises $50M in Series B round for Phase I CD47-targeting antibody

11:08 EDT 26 Mar 2019 | MedCity News

The company joins a small but growing list of firms developing drugs targeting CD47, the “don’t eat me” immune checkpoint. Another company, further ahead in development, is Forty Seven.

Original Article: Arch Oncology raises $50M in Series B round for Phase I CD47-targeting antibody

NEXT ARTICLE

More From BioPortfolio on "Arch Oncology raises $50M in Series B round for Phase I CD47-targeting antibody"

Advertisement
Quick Search
Advertisement
Advertisement